Skip to main content
Figure 6 | Radiation Oncology

Figure 6

From: Impact of head and neck cancer adaptive radiotherapy to spare the parotid glands and decrease the risk of xerostomia

Figure 6

Replanning benefit assessement: cumulated mean dose difference between the dose with replanning and the dose without replanning, in each of the parotid gland (ipsilateral and contralateral), for each of the 15 patients (6a), and corresponding estimated xerostomia risk (%) (6b). NTCP: normal tissue complication risk of xerostomia defined as a salivary flow ratio <25% of the pretreatment one [21].

Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us